ELANCO ANIMAL HEALTH INCORPORATED SHAREHOLDERS HAVE AN OPPORTUNITY TO RECOVER THEIR INVESTMENT LOSSES
Elanco Animal Health Incorporated
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NASDAQ: ELAN) securities between November 7, 2023 and June 26, 2024, inclusive. The lawsuit seeks to recover Elanco shareholders’ investment losses.
If you purchased securities in Elanco between November 7, 2023 and June 26, 2024, inclusive, and would like to discuss your legal rights and/or options, please click “Join Class Action” above.
According to the lawsuit, Defendants made misrepresentations concerning the timeline for U.S. Food and Drug Administration approval and commercial launch for two of the Company’s products, Zenrelia and Credelio Quattro.
If you wish to serve as lead plaintiff for the Class, you must file papers by December 6, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
pallocco@bernlieb.com